<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797013</url>
  </required_header>
  <id_info>
    <org_study_id>MK02-2020-01</org_study_id>
    <nct_id>NCT04797013</nct_id>
  </id_info>
  <brief_title>Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ</brief_title>
  <acronym>TRACEⅡ</acronym>
  <official_title>A Phase Ⅲ, Multicenter, Prospective, Randomized, Open Label, Blinded-endpoint (PROBE) Controlled Trial of Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) for Injection Versus Alteplase for Acute Ischemic Stroke Within 4.5 Hours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangzhou Recomgen Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase Ⅲ, Multicenter, Prospective, Randomized, Open Label, Blinded-endpoint (PROBE)&#xD;
      Controlled Trial of Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) for&#xD;
      Injection Versus Alteplase for Acute Ischemic Stroke Within 4.5 Hours&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To test the hypothesis that rhTNK-tPA is non-inferior to alteplase in thrombolysis treatment&#xD;
      when administered within 4.5 hours of ischemic stroke onset.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>multicenter, prospective, randomized, open label, blinded-endpoint (PROBE)，Parallel controls，Non-inferiority</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Scale(mRS)</measure>
    <time_frame>90 days</time_frame>
    <description>Proportion of subjects with mRS(0-1) at 90 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale(mRS)</measure>
    <time_frame>90 days</time_frame>
    <description>Proportion of subjects with mRS(0-2) at 90 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>24 hours，day7</time_frame>
    <description>Proportion of subjects with NIHSS 0-1 at 24 hours and 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>90 days</time_frame>
    <description>Quality of life measured by EQ-5D scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel (BI)</measure>
    <time_frame>90 days</time_frame>
    <description>Global function of daily living defined as BI ≥ 95 at 90 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale(mRS)</measure>
    <time_frame>90 days</time_frame>
    <description>Ordinal distribution of mRS at 90 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>24 hours，day7</time_frame>
    <description>Proportion of subjects with NIHSS score ≥ 4 improved compared with baseline at 24 hours and 7 days.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Symptomatic intracranial hemorrhage(sICH)</measure>
    <time_frame>36 hours</time_frame>
    <description>Proportion of subjects with symptomatic intracranial hemorrhage (sICH) at 36 hours.( defined by ECASSIII)</description>
  </other_outcome>
  <other_outcome>
    <measure>Asymptomatic intracranial hemorrhage</measure>
    <time_frame>90 days</time_frame>
    <description>The incidence of asymptomatic intracranial hemorrhage at 90 days.</description>
  </other_outcome>
  <other_outcome>
    <measure>PH2 intracranial hemorrhage</measure>
    <time_frame>90 days</time_frame>
    <description>The incidence of PH2 intracranial hemorrhage within 90 days (according to SITS standards).</description>
  </other_outcome>
  <other_outcome>
    <measure>Any intracranial hemorrhage</measure>
    <time_frame>90 days</time_frame>
    <description>The incidence of any intracranial hemorrhage within 90 days.</description>
  </other_outcome>
  <other_outcome>
    <measure>Systematic bleeding</measure>
    <time_frame>90 days</time_frame>
    <description>The incidence of Systematic bleeding at 90 days.( defined by GUSTO）</description>
  </other_outcome>
  <other_outcome>
    <measure>Deaths</measure>
    <time_frame>90 days</time_frame>
    <description>Rate of Overall mortality at 90 days.</description>
  </other_outcome>
  <other_outcome>
    <measure>AEs/SAEs</measure>
    <time_frame>90 days</time_frame>
    <description>The incidence of adverse events(AEs) / severe adverse events(SAEs) at 90 days.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1430</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>rhTNK-tPA (0.25mg/kg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rhTNK-tPA (0.25mg/kg) is given as a single, intravenous bolus (within 5-10 seconds) immediately upon randomization. Maximum dose 25mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rt-PA (0.9mg/kg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10% dose of rt-PA (0.9 mg/kg) is given as bolus and the remainder in 1 hour. Maximum dose 90mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rt-PA</intervention_name>
    <description>Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.</description>
    <arm_group_label>rt-PA (0.9mg/kg)</arm_group_label>
    <other_name>Alteplase injection (rt-PA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhTNK-tPA</intervention_name>
    <description>Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.</description>
    <arm_group_label>rhTNK-tPA (0.25mg/kg)</arm_group_label>
    <other_name>Recombinant Human TNK Tissue-type Plasminogen Activator for Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years old, no gender limitation;&#xD;
&#xD;
          -  The time from onset to treatment was &lt; 4.5h;The time at which symptoms begin is&#xD;
             defined as &quot;the time at which they finally appear normal&quot;;&#xD;
&#xD;
          -  The clinical diagnosis was ischemic stroke (the diagnosis followed the Chinese&#xD;
             Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018);&#xD;
&#xD;
          -  MRS before onset was 0-1 points&#xD;
&#xD;
          -  Baseline NIHSS 5-25(both included);&#xD;
&#xD;
          -  Informed consent from the patient or surrogate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intended to proceed endovascular treatment;&#xD;
&#xD;
          -  NIHSS consciousness score &gt;2;&#xD;
&#xD;
          -  Allergy to tenecteplase or alteplase;&#xD;
&#xD;
          -  Past history of intracranial hemorrhage ;&#xD;
&#xD;
          -  A history of severe head trauma or stroke within 3 months;&#xD;
&#xD;
          -  A history of intracranial or spinal surgery within 3 months;&#xD;
&#xD;
          -  A history of gastrointestinal or urinary bleeding within 3 weeks;&#xD;
&#xD;
          -  2 weeks of major surgery;&#xD;
&#xD;
          -  Arterial puncture was performed at the hemostasis site that was not easily compressed&#xD;
             within 1 week;&#xD;
&#xD;
          -  Intracranial tumors (except neuroectodermal tumors, such as meningiomas), large&#xD;
             intracranial aneurysms;&#xD;
&#xD;
          -  Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular&#xD;
             hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.);&#xD;
&#xD;
          -  Active visceral bleeding;&#xD;
&#xD;
          -  Aortic arch dissection was found;&#xD;
&#xD;
          -  After active antihypertensive treatment, hypertension is still not under control:&#xD;
             systolic blood pressure ≥180 mm Hg, or diastolic blood pressure ≥100 mm Hg;&#xD;
&#xD;
          -  Propensity for acute bleeding, including platelet counts of less than 100×109/ L or&#xD;
             otherwise;&#xD;
&#xD;
          -  Blood glucose &lt;2.8 mmol/L or &gt;22.22 mmol/L;&#xD;
&#xD;
          -  Oral warfarin anticoagulant with INR&gt;1.7 or PT&gt;15 s;&#xD;
&#xD;
          -  Heparin treatment was received within 24 h;&#xD;
&#xD;
          -  Thrombin inhibitors or factor Xa inhibitors were used within 48 h;&#xD;
&#xD;
          -  Head CT or MRI showed a large infarction (infarcted area &gt; 1/3 of the middle cerebral&#xD;
             artery);&#xD;
&#xD;
          -  Subjects who are unable or unwilling to cooperate due to hemiplegia (Todd's palsy)&#xD;
             after epileptic seizure or other neurological/psychiatric disorders;&#xD;
&#xD;
          -  Pregnant women, lactating women, or subjects who do not agree to use effective&#xD;
             contraception during the trial;&#xD;
&#xD;
          -  Participation in other clinical trials within 3 months prior to screening;&#xD;
&#xD;
          -  Unsuitability or participation in this study as judged by the Investigator may result&#xD;
             in subjects being exposed to greater risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Sun</last_name>
    <role>Study Director</role>
    <affiliation>IRB of Beijing Tiantan Hospital,Capital Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YongJun Wang</last_name>
    <phone>13911172565</phone>
    <email>yongjunwang111@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ShuYa Li</last_name>
    <email>shuyali85@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first affiliated hospital of ustc</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>guoping wang</last_name>
      <phone>18900518512</phone>
      <email>18900518512@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The people's hospltal of xuancheng city</name>
      <address>
        <city>Xuancheng</city>
        <state>Anhui</state>
        <zip>242000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>renping hu</last_name>
      <phone>13956600960</phone>
      <email>hrp.66@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing luhe hospital capital medical university</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>huishan du</last_name>
      <phone>13910639016</phone>
      <email>dhs139106@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongjun Wang</last_name>
      <email>yongjunwang111@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Yongjun Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chongqing Three Gorges Central Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>404100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shengli chen</last_name>
      <phone>13896226960</phone>
      <email>2271487396@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first hospital of lanzhou university</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jun chen</last_name>
      <phone>13993193823</phone>
      <email>cj_0158@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial Hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Guangdong</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yefeng cai</last_name>
      <phone>13631333842</phone>
      <email>caiyefeng@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yue bei people's hospital</name>
      <address>
        <city>Shaoguan</city>
        <state>Guangdong</state>
        <zip>512000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>junbin chen</last_name>
      <phone>13500205898</phone>
      <email>CJBCL0397@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guizhou provincial people's hospital</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiao hu</last_name>
      <phone>18096105119</phone>
      <email>18096105119@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated hospital of chengde medical university</name>
      <address>
        <city>Chengde</city>
        <state>Hebei</state>
        <zip>067000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>liang zhao</last_name>
      <phone>15633142910</phone>
      <email>liangzhao@163.om</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first hospital of hebei medical university</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yanyong wang</last_name>
      <phone>18633889676</phone>
      <email>13223455938@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the Third Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>junyan liu</last_name>
      <phone>18533112729</phone>
      <email>junyanliu2003@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tangshan Workers ' Hospital</name>
      <address>
        <city>Tangshan</city>
        <state>Hebei</state>
        <zip>063000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jing liu</last_name>
      <phone>15903159765</phone>
      <email>angel.jsea@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of hebei north university</name>
      <address>
        <city>Zhangjiakou</city>
        <state>Hebei</state>
        <zip>075000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>qian xue</last_name>
      <phone>13393246609</phone>
      <email>xueqian6166@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daqing Oilfield General Hospital</name>
      <address>
        <city>Daqing</city>
        <state>Heilongjiang</state>
        <zip>163000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xueshuang dong</last_name>
      <phone>15804593999</phone>
      <email>running.s@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 2ad affiliated hospital of harbin medical university</name>
      <address>
        <city>Haerbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lihua wang</last_name>
      <phone>13100881600</phone>
      <email>wanglh211@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second People's Hospital of Jiaozuo City</name>
      <address>
        <city>Jiaozuo</city>
        <state>Henan</state>
        <zip>454150</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhiping li</last_name>
      <phone>13839182756</phone>
      <email>13839182756@139.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanyang central hospital</name>
      <address>
        <city>Nanyang</city>
        <state>Henan</state>
        <zip>473000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>baochao zhang</last_name>
      <phone>18538953366</phone>
      <email>zbc177777@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanyang Nanshi Hospital</name>
      <address>
        <city>Nanyang</city>
        <state>Henan</state>
        <zip>473000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zaolong peng</last_name>
      <phone>13803876728</phone>
      <email>18530696963@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nayang second general hospital</name>
      <address>
        <city>Nanyang</city>
        <state>Henan</state>
        <zip>473000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yan song</last_name>
      <phone>13633778993</phone>
      <email>1136811893@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pingmei Shenma Medical Group General Hospital</name>
      <address>
        <city>Pingdingshan</city>
        <state>Henan</state>
        <zip>467000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hongwei zhang</last_name>
      <phone>13949457905</phone>
      <email>jsjyan1zhanghongwei@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinxiang first people's hospital</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <zip>453000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhiyong guo</last_name>
      <phone>15670505287</phone>
      <email>guozhiyong612@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinyang central hospital</name>
      <address>
        <city>Xinyang</city>
        <state>Henan</state>
        <zip>464000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hao li</last_name>
      <phone>13503761500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of zhengzhou university</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yuming shi</last_name>
      <phone>13903711125</phone>
      <email>13903711125@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The central hospital of wuhan</name>
      <address>
        <city>Wuhan</city>
        <state>Hunan</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ping jing</last_name>
      <phone>13667216889</phone>
      <email>jing51118@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inner Mongolia Baotou Hospita</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <zip>014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>dong wang</last_name>
      <phone>15540869818</phone>
      <email>nmbtwd@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Chifeng University</name>
      <address>
        <city>Chifeng</city>
        <state>Inner Mongolia</state>
        <zip>024000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>weili zhao</last_name>
      <phone>18104768065</phone>
      <email>wlzhao1968@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kashkten Mongolian Medicine Hospital</name>
      <address>
        <city>Chifeng</city>
        <state>Inner Mongolia</state>
        <zip>024000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhiguo lu</last_name>
      <phone>13722169555</phone>
      <email>1073281716@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inner Mongolia People'S Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <zip>010000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>runxiu zhu</last_name>
      <phone>18047191885</phone>
      <email>zhurunxiu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huai an second people's hospital</name>
      <address>
        <city>Huaian</city>
        <state>Jiangsu</state>
        <zip>223001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>liandong zhao</last_name>
      <phone>15061232828</phone>
      <email>zldong@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu taizhou people's hopital</name>
      <address>
        <city>Taizhou</city>
        <state>Jiangsu</state>
        <zip>225300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ying liu</last_name>
      <phone>13952618801</phone>
      <email>13952618801@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Xuzhou Mining Group</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>qingxiu zhang</last_name>
      <phone>15052009658</phone>
      <email>zhangqingxiu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xuzhou central hospital</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>guofang chen</last_name>
      <phone>18952172823</phone>
      <email>cgfxdd@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Third Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>youqing deng</last_name>
      <phone>15270030889</phone>
      <email>youqing1969@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yi yang</last_name>
      <phone>13756661217</phone>
      <email>doctoryangyi@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jilin neuropsychiaric hospital</name>
      <address>
        <city>Siping</city>
        <state>Jilin</state>
        <zip>136000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jianhua gao</last_name>
      <phone>18643462000</phone>
      <email>spgaojianhua@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tonghua Central Hospital</name>
      <address>
        <city>Tonghua</city>
        <state>Jilin</state>
        <zip>134000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>junfeng gao</last_name>
      <phone>13304455156</phone>
      <email>gaojunfeng968@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meihekou Central Hospital</name>
      <address>
        <city>Tonghua</city>
        <state>Jilin</state>
        <zip>135000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hong yu</last_name>
      <phone>13844564195</phone>
      <email>2823974848@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Firet Affiliated Hospital of Jinzhou Medical University</name>
      <address>
        <city>Jinzhou</city>
        <state>Liaoning</state>
        <zip>121000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xuewen liu</last_name>
      <phone>13940644988</phone>
      <email>sjnklxw@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central hospital affiliated to shenyang medical college</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>runhui li</last_name>
      <phone>18002477116</phone>
      <email>lirh710717@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Northern War Zone, PLA</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>huisheng chen</last_name>
      <phone>13352452086</phone>
      <email>chszh@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first hospital of china medical university</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>chuansheng zhao</last_name>
      <phone>13940369251</phone>
      <email>zhaocs@cmu1h.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People'S Hospital of Shenyang</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YI SUI</last_name>
      <phone>13998352587</phone>
      <email>tjyiia@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linyi City People Hospital</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <zip>276000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongxing HAN</last_name>
      <phone>13516393172</phone>
      <email>han-hongxing@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tengzhou Central People's Hospital</name>
      <address>
        <city>Tengzhou</city>
        <state>Shandong</state>
        <zip>277559</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>deyang li</last_name>
      <phone>13561190369</phone>
      <email>lideyang0632@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yantai Yuhuangding Hosopital</name>
      <address>
        <city>Yantai</city>
        <state>Shandong</state>
        <zip>264000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ZHIGANG LIANG</last_name>
      <phone>13723987720</phone>
      <email>zgliang@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>qiang dong</last_name>
      <phone>qdong@shmu.edu.cn</phone>
      <email>qdong@shmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heping hospital affiliated to changzhi medical college</name>
      <address>
        <city>Changzhi</city>
        <state>Shanxi</state>
        <zip>046000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hong liu</last_name>
      <phone>15235528796</phone>
      <email>yujian80@163.om</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Chinese Medicine and Coal</name>
      <address>
        <city>Datong</city>
        <state>Shanxi</state>
        <zip>037000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>junhai wang</last_name>
      <phone>13753265757</phone>
      <email>wjh1964@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The fifth people's s hospital of datong</name>
      <address>
        <city>Datong</city>
        <state>Shanxi</state>
        <zip>037000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jiezhong wei</last_name>
      <phone>13834129435</phone>
      <email>sxdtyjz@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linfen central hospital</name>
      <address>
        <city>Linfen</city>
        <state>Shanxi</state>
        <zip>041000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hongguo dai</last_name>
      <phone>15935767592</phone>
      <email>daihongguo3199@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linfen people's hospital</name>
      <address>
        <city>Linfen</city>
        <state>Shanxi</state>
        <zip>041000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>junfang hao</last_name>
      <phone>13835360973</phone>
      <email>haojunfan2012@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>suiyi xu</last_name>
      <phone>15103513579</phone>
      <email>suiyixu@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanxi Cardiovascular Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiaofei chen</last_name>
      <phone>13099071970</phone>
      <email>xiaofei45@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xianyang Hospital of Yan ' an University</name>
      <address>
        <city>Xianyang</city>
        <state>Shanxi</state>
        <zip>712000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>weiwei wang</last_name>
      <phone>15929201829</phone>
      <email>5935328@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mianyang central hospital</name>
      <address>
        <city>Mianyang</city>
        <state>Sichuan</state>
        <zip>621000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yufeng tang</last_name>
      <phone>13981184028</phone>
      <email>dryufeng@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanxi provincial prople's hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Taiyuan</state>
        <zip>030000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>fengyun hu</last_name>
      <phone>13834233638</phone>
      <email>fengyun71@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>min lou</last_name>
      <phone>13958167260</phone>
      <email>loumingxc@vip.sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lishui Central Hospital</name>
      <address>
        <city>Lishui</city>
        <state>Zhejiang</state>
        <zip>323000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xueli cai</last_name>
      <phone>13967059836</phone>
      <email>Caixueli111@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taizhou Enze Medical Center ( Group )</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <zip>318000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shaofa ke</last_name>
      <phone>13566862208</phone>
      <email>kesf@enzemed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wenzhou Central Hospital</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>liya han</last_name>
      <phone>13806690212</phone>
      <email>wzeyhly@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, Yan B, Bush SJ, Thijs V, Scroop R, Simpson M, Brooks M, Asadi H, Wu TY, Shah DG, Wijeratne T, Zhao H, Alemseged F, Ng F, Bailey P, Rice H, de Villiers L, Dewey HM, Choi PMC, Brown H, Redmond K, Leggett D, Fink JN, Collecutt W, Kraemer T, Krause M, Cordato D, Field D, Ma H, O'Brien B, Clissold B, Miteff F, Clissold A, Cloud GC, Bolitho LE, Bonavia L, Bhattacharya A, Wright A, Mamun A, O'Rourke F, Worthington J, Wong AA, Levi CR, Bladin CF, Sharma G, Desmond PM, Parsons MW, Donnan GA, Davis SM; EXTEND-IA TNK Part 2 investigators. Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial. JAMA. 2020 Apr 7;323(13):1257-1265. doi: 10.1001/jama.2020.1511.</citation>
    <PMID>32078683</PMID>
  </reference>
  <reference>
    <citation>Burgos AM, Saver JL. Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke: Meta-Analysis of 5 Randomized Trials. Stroke. 2019 Aug;50(8):2156-2162. doi: 10.1161/STROKEAHA.119.025080. Epub 2019 Jul 18.</citation>
    <PMID>31318627</PMID>
  </reference>
  <reference>
    <citation>Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008 Sep 25;359(13):1317-29. doi: 10.1056/NEJMoa0804656.</citation>
    <PMID>18815396</PMID>
  </reference>
  <reference>
    <citation>Campbell BCV, Ma H, Ringleb PA, Parsons MW, Churilov L, Bendszus M, Levi CR, Hsu C, Kleinig TJ, Fatar M, Leys D, Molina C, Wijeratne T, Curtze S, Dewey HM, Barber PA, Butcher KS, De Silva DA, Bladin CF, Yassi N, Pfaff JAR, Sharma G, Bivard A, Desmond PM, Schwab S, Schellinger PD, Yan B, Mitchell PJ, Serena J, Toni D, Thijs V, Hacke W, Davis SM, Donnan GA; EXTEND, ECASS-4, and EPITHET Investigators. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. Lancet. 2019 Jul 13;394(10193):139-147. doi: 10.1016/S0140-6736(19)31053-0. Epub 2019 May 22. Erratum in: Lancet. 2020 Jun 20;395(10241):1906.</citation>
    <PMID>31128925</PMID>
  </reference>
  <reference>
    <citation>Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, Brott T, Cohen G, Davis S, Donnan G, Grotta J, Howard G, Kaste M, Koga M, von Kummer R, Lansberg M, Lindley RI, Murray G, Olivot JM, Parsons M, Tilley B, Toni D, Toyoda K, Wahlgren N, Wardlaw J, Whiteley W, del Zoppo GJ, Baigent C, Sandercock P, Hacke W; Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014 Nov 29;384(9958):1929-35. doi: 10.1016/S0140-6736(14)60584-5. Epub 2014 Aug 5. Review.</citation>
    <PMID>25106063</PMID>
  </reference>
  <reference>
    <citation>Kunz WG, Hunink MG, Almekhlafi MA, Menon BK, Saver JL, Dippel DWJ, Majoie CBLM, Jovin TG, Davalos A, Bracard S, Guillemin F, Campbell BCV, Mitchell PJ, White P, Muir KW, Brown S, Demchuk AM, Hill MD, Goyal M; HERMES Collaborators. Public health and cost consequences of time delays to thrombectomy for acute ischemic stroke. Neurology. 2020 Nov 3;95(18):e2465-e2475. doi: 10.1212/WNL.0000000000010867. Epub 2020 Sep 17.</citation>
    <PMID>32943483</PMID>
  </reference>
  <reference>
    <citation>Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, Siddiqui A, Ford I, Muir KW. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015 Apr;14(4):368-76. doi: 10.1016/S1474-4422(15)70017-7. Epub 2015 Feb 26.</citation>
    <PMID>25726502</PMID>
  </reference>
  <reference>
    <citation>Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, Rønning OM, Thommessen B, Amthor KF, Ihle-Hansen H, Kurz M, Tobro H, Kaur K, Stankiewicz M, Carlsson M, Morsund Å, Idicula T, Aamodt AH, Lund C, Næss H, Waje-Andreassen U, Thomassen L. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017 Oct;16(10):781-788. doi: 10.1016/S1474-4422(17)30253-3. Epub 2017 Aug 2.</citation>
    <PMID>28780236</PMID>
  </reference>
  <reference>
    <citation>Kheiri B, Osman M, Abdalla A, Haykal T, Ahmed S, Hassan M, Bachuwa G, Al Qasmi M, Bhatt DL. Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials. J Thromb Thrombolysis. 2018 Nov;46(4):440-450. doi: 10.1007/s11239-018-1721-3. Review.</citation>
    <PMID>30117036</PMID>
  </reference>
  <results_reference>
    <citation>Warner JJ, Harrington RA, Sacco RL, Elkind MSV. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke. Stroke. 2019 Dec;50(12):3331-3332. doi: 10.1161/STROKEAHA.119.027708. Epub 2019 Oct 30.</citation>
    <PMID>31662117</PMID>
  </results_reference>
  <results_reference>
    <citation>Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL; American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018 Mar;49(3):e46-e110. doi: 10.1161/STR.0000000000000158. Epub 2018 Jan 24. Review. Erratum in: Stroke. 2018 Mar;49(3):e138. Stroke. 2018 Apr 18;:.</citation>
    <PMID>29367334</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu L, Chen W, Zhou H, Duan W, Li S, Huo X, Xu W, Huang L, Zheng H, Liu J, Liu H, Wei Y, Xu J, Wang Y; Chinese Stroke Association Stroke Council Guideline Writing Committee. Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of ischaemic cerebrovascular diseases. Stroke Vasc Neurol. 2020 Jun;5(2):159-176. doi: 10.1136/svn-2020-000378. Epub 2020 Jun 18. Review.</citation>
    <PMID>32561535</PMID>
  </results_reference>
  <results_reference>
    <citation>Ma H, Campbell BCV, Parsons MW, Churilov L, Levi CR, Hsu C, Kleinig TJ, Wijeratne T, Curtze S, Dewey HM, Miteff F, Tsai CH, Lee JT, Phan TG, Mahant N, Sun MC, Krause M, Sturm J, Grimley R, Chen CH, Hu CJ, Wong AA, Field D, Sun Y, Barber PA, Sabet A, Jannes J, Jeng JS, Clissold B, Markus R, Lin CH, Lien LM, Bladin CF, Christensen S, Yassi N, Sharma G, Bivard A, Desmond PM, Yan B, Mitchell PJ, Thijs V, Carey L, Meretoja A, Davis SM, Donnan GA; EXTEND Investigators. Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke. N Engl J Med. 2019 May 9;380(19):1795-1803. doi: 10.1056/NEJMoa1813046. Erratum in: N Engl J Med. 2021 Apr 1;384(13):1278.</citation>
    <PMID>31067369</PMID>
  </results_reference>
  <results_reference>
    <citation>Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, Cheripelli B, Cho TH, Fazekas F, Fiehler J, Ford I, Galinovic I, Gellissen S, Golsari A, Gregori J, Günther M, Guibernau J, Häusler KG, Hennerici M, Kemmling A, Marstrand J, Modrau B, Neeb L, Perez de la Ossa N, Puig J, Ringleb P, Roy P, Scheel E, Schonewille W, Serena J, Sunaert S, Villringer K, Wouters A, Thijs V, Ebinger M, Endres M, Fiebach JB, Lemmens R, Muir KW, Nighoghossian N, Pedraza S, Gerloff C; WAKE-UP Investigators. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. N Engl J Med. 2018 Aug 16;379(7):611-622. doi: 10.1056/NEJMoa1804355. Epub 2018 May 16.</citation>
    <PMID>29766770</PMID>
  </results_reference>
  <results_reference>
    <citation>Seners P, Turc G, Maïer B, Mas JL, Oppenheim C, Baron JC. Incidence and Predictors of Early Recanalization After Intravenous Thrombolysis: A Systematic Review and Meta-Analysis. Stroke. 2016 Sep;47(9):2409-12. doi: 10.1161/STROKEAHA.116.014181. Epub 2016 Jul 26. Review.</citation>
    <PMID>27462117</PMID>
  </results_reference>
  <results_reference>
    <citation>Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, Roy D, Jovin TG, Willinsky RA, Sapkota BL, Dowlatshahi D, Frei DF, Kamal NR, Montanera WJ, Poppe AY, Ryckborst KJ, Silver FL, Shuaib A, Tampieri D, Williams D, Bang OY, Baxter BW, Burns PA, Choe H, Heo JH, Holmstedt CA, Jankowitz B, Kelly M, Linares G, Mandzia JL, Shankar J, Sohn SI, Swartz RH, Barber PA, Coutts SB, Smith EE, Morrish WF, Weill A, Subramaniam S, Mitha AP, Wong JH, Lowerison MW, Sajobi TT, Hill MD; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015 Mar 12;372(11):1019-30. doi: 10.1056/NEJMoa1414905. Epub 2015 Feb 11.</citation>
    <PMID>25671798</PMID>
  </results_reference>
  <results_reference>
    <citation>Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, San Román L, Serena J, Abilleira S, Ribó M, Millán M, Urra X, Cardona P, López-Cancio E, Tomasello A, Castaño C, Blasco J, Aja L, Dorado L, Quesada H, Rubiera M, Hernandez-Pérez M, Goyal M, Demchuk AM, von Kummer R, Gallofré M, Dávalos A; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015 Jun 11;372(24):2296-306. doi: 10.1056/NEJMoa1503780. Epub 2015 Apr 17.</citation>
    <PMID>25882510</PMID>
  </results_reference>
  <results_reference>
    <citation>Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, Albers GW, Cognard C, Cohen DJ, Hacke W, Jansen O, Jovin TG, Mattle HP, Nogueira RG, Siddiqui AH, Yavagal DR, Baxter BW, Devlin TG, Lopes DK, Reddy VK, du Mesnil de Rochemont R, Singer OC, Jahan R; SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015 Jun 11;372(24):2285-95. doi: 10.1056/NEJMoa1415061. Epub 2015 Apr 17.</citation>
    <PMID>25882376</PMID>
  </results_reference>
  <results_reference>
    <citation>Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, Schonewille WJ, Vos JA, Nederkoorn PJ, Wermer MJ, van Walderveen MA, Staals J, Hofmeijer J, van Oostayen JA, Lycklama à Nijeholt GJ, Boiten J, Brouwer PA, Emmer BJ, de Bruijn SF, van Dijk LC, Kappelle LJ, Lo RH, van Dijk EJ, de Vries J, de Kort PL, van Rooij WJ, van den Berg JS, van Hasselt BA, Aerden LA, Dallinga RJ, Visser MC, Bot JC, Vroomen PC, Eshghi O, Schreuder TH, Heijboer RJ, Keizer K, Tielbeek AV, den Hertog HM, Gerrits DG, van den Berg-Vos RM, Karas GB, Steyerberg EW, Flach HZ, Marquering HA, Sprengers ME, Jenniskens SF, Beenen LF, van den Berg R, Koudstaal PJ, van Zwam WH, Roos YB, van der Lugt A, van Oostenbrugge RJ, Majoie CB, Dippel DW; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015 Jan 1;372(1):11-20. doi: 10.1056/NEJMoa1411587. Epub 2014 Dec 17. Erratum in: N Engl J Med. 2015 Jan 22;372(4):394.</citation>
    <PMID>25517348</PMID>
  </results_reference>
  <results_reference>
    <citation>Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, Yan B, Dowling RJ, Parsons MW, Oxley TJ, Wu TY, Brooks M, Simpson MA, Miteff F, Levi CR, Krause M, Harrington TJ, Faulder KC, Steinfort BS, Priglinger M, Ang T, Scroop R, Barber PA, McGuinness B, Wijeratne T, Phan TG, Chong W, Chandra RV, Bladin CF, Badve M, Rice H, de Villiers L, Ma H, Desmond PM, Donnan GA, Davis SM; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015 Mar 12;372(11):1009-18. doi: 10.1056/NEJMoa1414792. Epub 2015 Feb 11.</citation>
    <PMID>25671797</PMID>
  </results_reference>
  <results_reference>
    <citation>Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, Dávalos A, Majoie CB, van der Lugt A, de Miquel MA, Donnan GA, Roos YB, Bonafe A, Jahan R, Diener HC, van den Berg LA, Levy EI, Berkhemer OA, Pereira VM, Rempel J, Millán M, Davis SM, Roy D, Thornton J, Román LS, Ribó M, Beumer D, Stouch B, Brown S, Campbell BC, van Oostenbrugge RJ, Saver JL, Hill MD, Jovin TG; HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016 Apr 23;387(10029):1723-31. doi: 10.1016/S0140-6736(16)00163-X. Epub 2016 Feb 18.</citation>
    <PMID>26898852</PMID>
  </results_reference>
  <results_reference>
    <citation>Fassbender K, Walter S, Grunwald IQ, Merzou F, Mathur S, Lesmeister M, Liu Y, Bertsch T, Grotta JC. Prehospital stroke management in the thrombectomy era. Lancet Neurol. 2020 Jul;19(7):601-610. doi: 10.1016/S1474-4422(20)30102-2. Review.</citation>
    <PMID>32562685</PMID>
  </results_reference>
  <results_reference>
    <citation>Bivard A, Lin L, Parsonsb MW. Review of stroke thrombolytics. J Stroke. 2013 May;15(2):90-8. doi: 10.5853/jos.2013.15.2.90. Epub 2013 May 31. Review.</citation>
    <PMID>24324944</PMID>
  </results_reference>
  <results_reference>
    <citation>Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, O'Brien B, Bladin C, McElduff P, Allen C, Bateman G, Donnan G, Davis S, Levi C. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012 Mar 22;366(12):1099-107. doi: 10.1056/NEJMoa1109842.</citation>
    <PMID>22435369</PMID>
  </results_reference>
  <results_reference>
    <citation>Coutts SB, Dubuc V, Mandzia J, Kenney C, Demchuk AM, Smith EE, Subramaniam S, Goyal M, Patil S, Menon BK, Barber PA, Dowlatshahi D, Field T, Asdaghi N, Camden MC, Hill MD; TEMPO-1 Investigators. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. Stroke. 2015 Mar;46(3):769-74. doi: 10.1161/STROKEAHA.114.008504. Epub 2015 Feb 12.</citation>
    <PMID>25677596</PMID>
  </results_reference>
  <results_reference>
    <citation>Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, Yan B, Bush SJ, Dewey HM, Thijs V, Scroop R, Simpson M, Brooks M, Asadi H, Wu TY, Shah DG, Wijeratne T, Ang T, Miteff F, Levi CR, Rodrigues E, Zhao H, Salvaris P, Garcia-Esperon C, Bailey P, Rice H, de Villiers L, Brown H, Redmond K, Leggett D, Fink JN, Collecutt W, Wong AA, Muller C, Coulthard A, Mitchell K, Clouston J, Mahady K, Field D, Ma H, Phan TG, Chong W, Chandra RV, Slater LA, Krause M, Harrington TJ, Faulder KC, Steinfort BS, Bladin CF, Sharma G, Desmond PM, Parsons MW, Donnan GA, Davis SM; EXTEND-IA TNK Investigators. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke. N Engl J Med. 2018 Apr 26;378(17):1573-1582. doi: 10.1056/NEJMoa1716405.</citation>
    <PMID>29694815</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Yongjun Wang</investigator_full_name>
    <investigator_title>President of Beijing Tiantan Hospital, Capital Medical University, Director of Neurology Center</investigator_title>
  </responsible_party>
  <keyword>rhTNK-tPA</keyword>
  <keyword>acute</keyword>
  <keyword>stroke</keyword>
  <keyword>phaseⅢ</keyword>
  <keyword>Acute Ischemic Stroke</keyword>
  <keyword>rt-PA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Plasminogen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

